CVS Health stock rating maintained at Overweight by Cantor Fitzgerald

Published 10/10/2025, 12:48
CVS Health stock rating maintained at Overweight by Cantor Fitzgerald

Investing.com - Cantor Fitzgerald has reiterated its Overweight rating on CVS Health (NYSE:CVS), a $97 billion healthcare giant that has seen its stock surge nearly 77% year-to-date, with a price target of $78.00, according to a research note released Friday. According to InvestingPro, analysts maintain a bullish consensus on the stock, with price targets ranging from $70 to $103.

The firm noted that CVS Health’s slight decline in Medicare Advantage Star ratings was "more positive than feared" and represented "the largest upside in ratings" in their view. Cantor Fitzgerald anticipates a positive market response to CVS maintaining over 80% of its ratings at high levels. The company’s strong operational performance is reflected in its GOOD Financial Health score from InvestingPro.

The research highlighted that intra-quarter concerns had emerged regarding CVS Health’s ability to maintain its leading position in the Medicare Star Ratings program, which affects reimbursement rates and enrollment periods for Medicare Advantage plans.

Key contracts mentioned in the analysis include H5522, a 1.3 million member contract representing 31% of CVS Health’s Medicare Advantage membership, and H5521, a 1.1 million member contract accounting for 26% of membership, both of which achieved 4.5-Star Ratings.

The Star Ratings are significant for CVS Health as they directly impact the company’s Medicare Advantage business, which represents a substantial portion of its healthcare benefits segment. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, one of 1,400+ detailed company analyses available to subscribers.

In other recent news, CVS Health’s subsidiary, Omnicare, has filed for Chapter 11 bankruptcy protection following a significant $949 million judgment over allegations of improper prescription drug dispensing to long-term care patients. The bankruptcy filing lists Omnicare’s assets at a minimum of $100 million, with liabilities ranging from $1 billion to $10 billion, as the company seeks to address financial challenges and litigation issues. Additionally, CVS Health has been affected by trends in the Arizona market, where Medicaid disenrollment is impacting several healthcare insurers. Cantor Fitzgerald has maintained an Overweight rating on CVS Health, setting a price target of $78.00, despite these challenges. In related developments, Amazon has announced plans to expand its pharmacy services, which could further influence CVS Health’s market position. The expansion involves Amazon’s pharmacy division beginning to fill prescriptions at kiosks in its One Medical facilities starting in December. Meanwhile, Cantor Fitzgerald reiterated a Neutral rating for Molina Healthcare, another company affected by the Arizona Medicaid trends. These developments highlight ongoing shifts and challenges in the healthcare and pharmacy sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.